Traztuzumab (Herceptin), a monoclonal antibody against the HER-2 receptor, has been widely established in breast cancer patients overexpressing HER-2 with significantly improved survival rates reported in these patients (Treish et al, 2000). Here, ERBB2 is linked to breast cancer.